Wuhan Keqian Biology Co Ltd

SHG:688526 China Biotechnology
Market Cap
$1.01 Billion
CN¥7.44 Billion CNY
Market Cap Rank
#13805 Global
#3575 in China
Share Price
CN¥15.97
Change (1 day)
-0.25%
52-Week Range
CN¥14.82 - CN¥19.33
All Time High
CN¥47.40
About

Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.

Wuhan Keqian Biology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 19.42%

Wuhan Keqian Biology Co Ltd (688526) has an Asset Resilience Ratio of 19.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥922.80 Million
Cash + Short-term Investments
Total Assets
CN¥4.75 Billion
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Wuhan Keqian Biology Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Keqian Biology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥922.80 Million 19.42%
Total Liquid Assets CN¥922.80 Million 19.42%

Asset Resilience Insights

  • Good Liquidity Position: Wuhan Keqian Biology Co Ltd maintains a healthy 19.42% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Wuhan Keqian Biology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Keqian Biology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Wuhan Keqian Biology Co Ltd (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Wuhan Keqian Biology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 16.00% CN¥719.51 Million CN¥4.50 Billion +0.05pp
2023-12-31 15.95% CN¥745.04 Million CN¥4.67 Billion +0.58pp
2022-12-31 15.37% CN¥674.83 Million CN¥4.39 Billion +9.65pp
2021-12-31 5.72% CN¥212.95 Million CN¥3.73 Billion -2.96pp
2020-12-31 8.68% CN¥270.00 Million CN¥3.11 Billion --
pp = percentage points